June 2022 - Hybrid meeting, Antwerp

​​​​​Meeting objectives: 

  • HPV prevention and control in People Living With HIV 
    • Discuss and review the HPV vaccine schedule for People Living With HIV 
    • Discuss HPV screening of People Living With HIV 
    • Discuss and review the management of women with HIV who are HPV positives
  • Benefits and Challenges of Immunobridging trials 
    • Discuss availability and use of different HPV immunoassays
    • Discuss challenges and prospects of immunobridging trials for evaluating current and future HPV vaccines
  • DNA Methylation as a triage tool for cervical cancer screening
    • Provide an overview of the use of DNA methylation in the oncology field
    • Provide an overview of different DNA methylation assays and methods
    • Discuss the use of DNA methylation as a novel biomarker for triage of human papillomavirus (HPV) positive women at screening

Introduction video

Thursday, 2 June 2022

SESSION 1 : WELCOME AND INTRODUCTION

  • Welcome & Introduction
    Alex Vorsters & Dur-e-Nayab Waheed  (pdf, video)

SESSION 2: HPV PREVENTION AND CONTROL IN PEOPLE LIVING WITH HIV

Chairs: Maribel Almonte & Silvia de Sanjose

  • Global HIV Epidemiology and the intersection with HPV and cervical cancer burden
    Gary Clifford (pdf, video)

  • ​Performance and effectiveness of screeningtriage strategies for cervical precancer among women living with HIV
    Helen Kelly (pdf, video)

  • Questions and Discussion (video)

  • Management of women with HIV who are HPV positive
    Hennie Botha (pdf, video)

  • Improving HPV & precancer treatment among WLWH in LMICs: The Low Hanging Fruit
    Chemtai Mungo (pdf, video)

  • Questions and Discussion (video)

  • HPV vaccination in people living with HIV
    Sinead Delany-Moretlwe (pdf, video)​

  • Questions and Discussion (video)

  • Keynote lecture: Prevention of anal cancer in males and females living with HIV
    Joel Palefsky 

SESSION 3: BENEFITS AND CHALLENGES OF IMMUNOBRIDGING

Chairs: Partha Basu & Deborah Watson-Jones

  • Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Importance of international units for reporting immune response
    Carina Eklund (pdf, video)

  • Neutralizing and cross-neutralizing antibody levels to human papillomavirus following vaccination
    Filipe Colaço Mariz (pdf, video)

  • Questions and Discussion (video)

  • Current status of using urine samples to monitor HPV vaccination status
     Alex Vorsters & Laura Téblick  (pdf, video)​

  • Monitoring of HPV vaccination programs
    Iacopo Baussano 

  • Questions and Discussion (video)

  • Update on April 2022 SAGE advice on HPV schedule optimization and the permissive single dose recommendation in younger women
    Paul Bloem (pdf, video)

  • One dose modelling study in India
    Iacopo Baussano

  • Questions and Discussion (video)

SESSION 3A: PANEL DISCUSSION
One dose

Chairs: Margaret Stanley & Peter Dull

  • Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial
    Nelly Mugo (Pdf, video)

  • The DoRIS trial results to M36-immunogenicity of 1 dose of gardasil9®and cervarix® in Tanzanian girls aged 9-14Y and M24 immunobridging results
    Deborah Watson-Jones (pdf, video)​
     
  • Costa Rica HPV Vaccine Trials
    Aimee Kreimer (pdf, video)​

  • Multicentric cohort study to compare efficacy of a single dose of 4-HPV vaccine compared to two &three doses in 10-18 yr old females in India
    Partha Basu (pdf, video)​
     
  • Hope Study: Population impact of a single HPV vaccine dose on HPV 16/18 prevalence among South African adolescent girls
    Sinead Delany-Moretlwe (pdf, video)
     
  • Panel discussion - Speakers and participants (video)
    Nelly Mugo, Deborah Watson-Jones, Aimee Kreimer, Sinead Delany-Moretlwe, Paul Bloem, Gary Clifford, Partha Basu  

Topics:

  • One dose
  • One dose use in women living with HIV
  • Implementation of one dose in LMICs

Friday, 3 June 2022

SESSION 4: DNA METHYLATION AS A TRIAGE TOOL FOR CERVICAL CANCER SCREENING
Chairs: Mario Poljak & Kate Cuschieri

  • Welcome
    Alex Vorsters

  • Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia 
    Karolina Louvanto (pdf, video)​
     
  • Overview of different DNA methylation assays used in HPV screening
    Mariam El-Zein (pdf, video)
     
  • Methylation patterns of host cell DNA and the heterogeneous nature of cervical pre-cancer
    Daniëlle Heideman (video)
     
  • Methylation of viral DNA and combined viral and host DNA methylation
    Jack Cuzick
     
  • DNA methylation testing on clinician-collected cervical and self-collected vaginal samples for identification of cervical lesions in high-risk HPV positive women
    Johannes Berkhof (pdf, video)

  • Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women
    Megan Clarke (pdf, video)
     
  • Questions and Discussions. (video)

  • Could DNA methylation be used as a primary cervical screening method?
    Belinda Nedjai (pdf, video)
     
  • Evaluation of  cervical screening strategies using methylation markers in WLHIV
    Chris Meijer (pdf, video)
     
  • The standing of self-collected urine samples for DNA methylation in cervical screening
    Severien Van Keer  (pdf, video)

  • Questions and Discussions (video)

SESSION 5: BREAKOUT SESSION
Chairs: Alex Vorsters & Marc Arbyn

  1. Breakout Group 1: HPV Prevention and Control in HIV Positives – challenges and lessons learnt
    Chairs: Marc Steben & Sharon Hanley

  2. Breakout Group 2: Benefits and Challenges of Immunobridging
    Chairs: Eduardo Franco & Suzanne Garland

  3. Breakout Group 3: DNA Methylation as a triage tool for HPV positives – challenges and lessons learnt
    Chairs: Murat Gultekin & Johannes Berkhof

Plenary Feedback

SESSION 6: MEETING CONCLUSION AND CLOSING REMARKS
Chairs: Narendra Kumar Arora & Alex Vorsters 

  • Conclusions and Concluding Remarks (pdf, video)​